Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
FleuryBSP:FLRY3 +3.21%90 EV-to-EBITDA is 5.17 as of Jul. 29, 2026, which is 40% below its 10-year median of 8.65. GuruFocus rates BSP:FLRY3 with a GF Score™ of 90/100 and a GF Value™ of R$17.54 (Fairly Valued). The stock has 5 warning signs investors should review. Among 118 Medical Diagnostics & Research companies, Fleury ranks better than 85.59% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Fleury's enterprise value is R$12,576 Mil.
Fleury's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was R$2,433 Mil. Therefore, Fleury's EV-to-EBITDA for today is 5.17.
The historical rank and industry rank for Fleury's EV-to-EBITDA or its related term are showing as below:
BSP:FLRY3'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.33 Med: 8.65 Max: 16.63
Current: 5.17
During the past 13 years, the highest EV-to-EBITDA of Fleury was 16.63. The lowest was 4.33. And the median was 8.65.
BSP:FLRY3's EV-to-EBITDA is ranked better than 85.59% of 118
companies
in the Medical Diagnostics & Research industry
Industry Median: 15.53
vs BSP:FLRY3: 5.17
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2026-07-29), Fleury's stock price is R$17.06.
Fleury's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was R$1.158. Therefore, Fleury's PE Ratio (TTM) for today is 14.73.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Fleury (BSP:FLRY3) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Fleury's share price for today is R$17.06.
Fleury's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$1.158.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Fleury's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSP:FLRY3 vs TMO, DHR, IDXX: EV-to-EBITDA Comparison
For the Diagnostics & Research subindustry, Fleury's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fleury EV-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Fleury's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Fleury's EV-to-EBITDA falls into.
Fleury's current Enterprise Value is R$12,576 Mil.
Fleury's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$2,433 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fleury (BSP:FLRY3) has a EV-to-EBITDA of 5.17 as of Jul. 29, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Fleury. This is 40% below median its historical median of 8.65. Over the past decade, Fleury's EV-to-EBITDA has ranged from 4.33 to 16.63. According to the industry distribution chart, Fleury ranks #17 out of 118 companies in the Medical Diagnostics & Research industry, placing it in the top 14.4%.
Is Fleury's EV-to-EBITDA too high?
Fleury's current EV-to-EBITDA of 5.17 is 40% below median its 10-year median of 8.65. Over the past 10 years, this metric has ranged from a low of 4.33 to a high of 16.63. The Medical Diagnostics & Research industry median EV-to-EBITDA is 15.53. Fleury's value of 5.17 is 66.7% below this industry median. Based on the distribution chart, Fleury ranks #17 out of 118 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Fleury has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Fleury's EV-to-EBITDA compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Fleury ranks #17 out of 118 companies for EV-to-EBITDA. This places Fleury in the top 14% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 15.53. Fleury's value of 5.17 is 66.7% below this benchmark. Historically, Fleury's own EV-to-EBITDA has ranged from 4.33 to 16.63 over the past decade. While the company's 10-year median is 8.65 vs. the industry median of 15.53, Fleury has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Diagnostics & Research company?
The median EV-to-EBITDA among Medical Diagnostics & Research companies is 15.53, based on 118 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fleury's current EV-to-EBITDA of 5.17 is 66.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Fleury. For the Medical Diagnostics & Research industry, the median EV-to-EBITDA is 15.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fleury's current EV-to-EBITDA is 5.17, which is 40% below median its own 10-year median of 8.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fleury stock overvalued right now?
Based on GuruFocus' analysis, Fleury (BSP:FLRY3) is currently considered Fairly Valued. The stock's GF Value™ is R$17.54, compared to a current price of R$17.06 — trading 2.7% below its estimated fair value. The current EV-to-EBITDA is 5.17, which is 40% below median its 10-year median of 8.65 and 66.7% below the Medical Diagnostics & Research industry median of 15.53. Fleury's overall GF Score™ is 90/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Fleury (BSP:FLRY3), the current EV-to-EBITDA is 5.17 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fleury (BSP:FLRY3) Overvalued in 2026?
Based on GuruFocus' analysis, Fleury stock appears to be undervalued.
The current stock price of R$17.06 is trading 2.7% below its estimated GF Value™ of R$17.54.
GuruFocus considers Fleury to be Fairly Valued.
Key valuation signals for BSP:FLRY3:
EV-to-EBITDA: 5.17 (40% below median its 10-year median of 8.65)
GF Value™: R$17.54 vs. price of R$17.06 (2.7% below fair value)
Industry Position: 66.7% below the Medical Diagnostics & Research median (#17 of 118)
No single metric tells the full story. See the BSP:FLRY3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fleury SA is engaged in the provision of medical services in the diagnostic, laboratory support (Lab-to-Lab), infusions, clinical analysis, health management, medical care, orthopedics and ophthalmology, fertility, infusion areas and toxicological exams, among others. The company offers diagnostic medicine through physical service units and mobile diagnostic services for consumers. It also provides diagnostic support services to laboratories and hospitals. In addition, the company operates clinics and services in areas such as infusion therapy, orthopedics, ophthalmology, reproductive medicine, and oncology. It has two reportable business segments: Diagnostic Medicine and Integrated Medicine. The maximum revenue is generated from the Diagnostic Medicine Segment.
90GF Score
Get the complete analysis for BSP:FLRY3
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:FLRY3 has been successfully added to your 
